Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

2018 MPC-150-IM (rexlemestrocel-L; Mesoblast) Drug Analysis - ResearchAndMarkets.com

Research and Markets
Posted on: 15 Feb 18

The "Drug analysis: MPC-150-IM" drug pipelines has been added to ResearchAndMarkets.com's offering.

MPC-150-IM (rexlemestrocel-L; Mesoblast) consists of highly purified, immunoselected mesenchymal precursor cells (MPCs). These cells release a range of molecules that stimulate both blood vessel growth and regeneration of heart muscle, while also reducing scar formation and harmful inflammatory responses within the damaged tissues. These rare cells are isolated from tissues around the donor's blood vessels and then expanded in large numbers before being administered to patients.

Product Profiles

MPC-150-IM: Chronic heart failure (CHF)

List of Figures

Figure 21: Drug assessment summary of Farxiga for chronic heart failure

Figure 22: Farxiga sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017-26

List of Tables

Table 1: MPC-150-IM drug profile

Table 2: MPC-150-IM's late-phase trials in chronic heart failure

Table 3: MPC-150-IM sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017-26

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/km4fdq/2018_mpc150im?w=4

View source version on businesswire.com: http://www.businesswire.com/news/home/20180215005733/en/

Business Wire
www.businesswire.com

Last updated on: 15/02/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.